FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
13.94 USD
-0.16 (-1.15%)
Balance Sheet
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Total Cash
11.54M
128.66M
131.3M
273.87M
277.92M
1.39M
1.08M
835.43k
646.82k
500.8k
Total Cash %
126.91
1k
1.84k
12.57k
15.44k
100
100
100
100
Receivables
438k
615k
878k
257k
778k
214.52k
166.09k
128.59k
99.56k
77.09k
Receivables %
4.82
4.8
12.32
11.8
43.22
15.39
15.39
15.39
15.39
Inventories
3.21M
-129.28M
-878k
-257k
-
-247.66k
-191.75k
-148.46k
-114.95k
-89k
Inventories %
35.27
-1.01k
-12.32
-11.8
-
-17.77
-17.77
-17.77
-17.77
Payable
3.12M
13.46M
9.13M
4.34M
8.31M
1.21M
937.14k
725.58k
561.78k
434.95k
Payable %
34.26
105.07
128.07
199.4
461.72
86.85
86.85
86.85
86.85
Cap Ex
-1.81M
-1.36M
-864k
-686k
-4.59M
-485.48k
-375.88k
-291.03k
-225.33k
-174.46k
Cap Ex %
-19.91
-10.65
-12.13
-31.5
-255.17
-34.84
-34.84
-34.84
-34.84
